Drug Trial Radar · NCT04027387
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
Last checked: Nov 19, 2026Latest source record: Oct 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 14, 2019
Primary completion
Aug 18, 2021
Study completion Aug 18, 2021
Sponsor
- Lead sponsor
- TaiMed Biologics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Westat
- First posted
- Jul 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and behavior in the body of the experimental drug TMB-365 in people with HIV-1 infection. This will be the first test of TMB-365 in humans. One dose of the study drug is given to each participant, followed by 10 weeks of monitoring for safety and levels of the drug in the blood. The first group of participants will receive the lowest dose (400 mg). If no safety concerns are seen, the next group will begin at a higher dose (800 mg). If no safety concerns are seen in the second group, the third group will begin at the highest dose in this study (1600 mg).
Conditions
- HIV-1-infection
Interventions
TMB-365Biological
An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of a single 400mg dose of TMB-365Time frame: 10 weeks
- Safety of a single 800mg dose of TMB-365Time frame: 10 weeks
- Safety of a single 1600mg dose of TMB-365Time frame: 10 weeks
- Pharmacokinetics of a single 400mg dose of TMB-365Time frame: 4 weeks
- Pharmacokinetics of a single 800mg dose of TMB-365Time frame: 4 weeks
- Pharmacokinetics of a single 1600mg dose of TMB-365Time frame: 4 weeks
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Quest Clinical Research
San Francisco, California
Midway Immunology and Research Center
Ft. Pierce, Florida
Orlando Immunology Center
Orlando, Florida
University of Mississippi Medical Center Division of Infectious Diseases
Jackson, Mississippi
North Texas Infectious Disease Consultants
Dallas, Texas
Clinical Research PR, Inc
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.